Annals of Hematology最新文献_第9页

Efficacy of thiotepa-conditioned autologous stem-cell transplantation as consolidation therapy for primary leptomeningeal malignant lymphoma: a case report and review of literature. 噻替派条件自体干细胞移植作为原发性脑膜恶性淋巴瘤巩固治疗的疗效：病例报告和文献综述。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-10-01 DOI: 10.1007/s00277-024-06029-8

Tomohito Shimada, Kana Bando, Atsushi Takahata, Shigeo Toyota

{"title":"Efficacy of thiotepa-conditioned autologous stem-cell transplantation as consolidation therapy for primary leptomeningeal malignant lymphoma: a case report and review of literature.","authors":"Tomohito Shimada, Kana Bando, Atsushi Takahata, Shigeo Toyota","doi":"10.1007/s00277-024-06029-8","DOIUrl":"https://doi.org/10.1007/s00277-024-06029-8","url":null,"abstract":"<p><p>Primary leptomeningeal malignant lymphoma (PLML) is a rare subtype of primary central nervous system lymphoma (PCNSL). Treatment is often based on PCNSL, but currently there is no established treatment strategy due to its rarity. We report a case of a 46-year-old male diagnosed with PLML through cerebrospinal fluid cytology and flow cytometry, presenting with multiple cranial nerve palsies and L5 radiculopathy. The patient achieved complete remission (CR) with R-MPV (rituximab, methotrexate, procarbazine, and vincristine) combined with intrathecal chemotherapy (methotrexate, cytarabine, and prednisolone). This was followed by autologous stem-cell transplantation (ASCT) using a thiotepa-based conditioning regimen, resulting in sustained CR. A literature review on the use of ASCT for PLML revealed three reported cases, including ours, all achieving CR with ASCT and minimal adverse events. These findings suggest that ASCT can be a promising consolidation therapy for PLML. Further studies are needed to establish standardized treatment protocols for this rare condition.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment with Pola-R-mini-CHP for elderly relapsed and refractory mantle cell lymphoma. 用Pola-R-mini-CHP成功治疗老年复发和难治套细胞淋巴瘤。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-30 DOI: 10.1007/s00277-024-06024-z

Satoko Oka, Yuina Akagi, Kazuo Ono

引用次数: 0

A case of visual impairment due to HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia-M2 subtype. 一例儿童急性髓性白血病-M2亚型异体造血干细胞移植后因HHV-6脑炎导致的视力障碍。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-30 DOI: 10.1007/s00277-024-06030-1

Yan-Sha Pan, Hao Li, Min Yang, Chang-Ling Zhang, Lan Xiao, Chun-Yan Liu, Xue-Yan Deng, Xiu-Mei Xu, You Yang, Wen-Jun Liu

引用次数: 0

Is radiotherapy still the optimal initial choice for patients with early-stage low-grade follicular lymphoma in the modern era? A population-based study 放疗是否仍是现代早期低级别滤泡性淋巴瘤患者的最佳初始选择？一项基于人群的研究。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-28 DOI: 10.1007/s00277-024-06022-1

Wenshuai Zheng, Shenyu Wang, Yanchao Liang, Hongmei Ning

{"title":"Is radiotherapy still the optimal initial choice for patients with early-stage low-grade follicular lymphoma in the modern era? A population-based study","authors":"Wenshuai Zheng, Shenyu Wang, Yanchao Liang, Hongmei Ning","doi":"10.1007/s00277-024-06022-1","DOIUrl":"10.1007/s00277-024-06022-1","url":null,"abstract":"<div><p>Despite radiotherapy (RT) is recognized as preferred initial therapy for early-stage low-grade follicular lymphoma (FL) by many international practice guidelines, the medical oncologist has improperly underutilized RT, and diverse management strategies, including systemic therapy (ST), combined modality (CM) and watch and wait (WW), are still used. Except survival outcomes, previous studies concerned little about the treatment-related toxicity, which is also important factor in choosing initial management strategy, especially second primary malignancies (SPMs). The aim of this study was to compare the overall survival (OS) and the SPMs risk between different management strategies, which can provide guidance for the choice of optimal initial management strategy. Data was acquired from the Surveillance, Epidemiology, and End Results (SEER) database. Finally, A total 10,900 patients were identified, in which 930 cases developed SPMs. The use of radiotherapy (RT) has remained consistently low, with a utilization rate of around 20%, while most patients have received watchful waiting (WW) and systemic therapy (ST). In the rituximab era, multivariate analysis indicated that RT exhibited significantly superior OS and did not increase SPMs risk in comparison with ST and WW. At the same time, although there were no significant differences in OS between CM and RT, RT had significantly lower SPMs risk in comparison with CM. The use of RT improved the OS and did not increase the SPMs risk in comparison with other management strategies. Considering the low application rate of RT, oncologists should emphasize and increase the use of RT as an initial management strategy in patients with early-stage low-grade FL.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 11","pages":"4589 - 4598"},"PeriodicalIF":3.0,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-024-06022-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rosai-Dorfman-Destombes disease in adults: a single center experience 成人罗赛-多夫曼-多斯通贝病：单中心经验。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-27 DOI: 10.1007/s00277-024-06019-w

Emily Leung, Collin Pryma, Stephen Murphy, Rebecca Harrison, Erica Peterson, Peter W. K. Tsang, Julia Varghese, Xiaotian (Julie) You, Graham W. Slack, Brian F. Skinnider, Tony Ng, Sean Young, Steven Burrell, Ryan Stubbins, Howard Lim, Mollie Carruthers, Jan Dutz, Eli L. Diamond, Luke Y. C. Chen

{"title":"Rosai-Dorfman-Destombes disease in adults: a single center experience","authors":"Emily Leung, Collin Pryma, Stephen Murphy, Rebecca Harrison, Erica Peterson, Peter W. K. Tsang, Julia Varghese, Xiaotian (Julie) You, Graham W. Slack, Brian F. Skinnider, Tony Ng, Sean Young, Steven Burrell, Ryan Stubbins, Howard Lim, Mollie Carruthers, Jan Dutz, Eli L. Diamond, Luke Y. C. Chen","doi":"10.1007/s00277-024-06019-w","DOIUrl":"10.1007/s00277-024-06019-w","url":null,"abstract":"<div><p>Recent advances in Rosai-Dorfman-Destombes disease (RDD), notably molecular testing, targeted therapy, and PET-CT imaging, hold promise for better recognition and improved outcomes. This study presents patients diagnosed and treated in a “real world” setting, where navigating limited resources must be considered. This retrospective single-center review includes 15 adult patients diagnosed with RDD at Vancouver General Hospital between November 2015 and October 2023. The cohort comprised five males and ten females with a median age 53 years (range 19–80 years). All 15 patients had extra-nodal disease; 11 patients exclusively had extra-nodal disease, and four patients also had lymph node involvement. Seven patients had tissue next-generation sequencing, identifying <i>MAP2K1</i> mutations in four cases and a <i>KRAS</i> p.K117N mutation in one case that was treated with targeted therapy using trametinib. PET-CT was used for disease staging in four cases. Six patients with refractory disease tolerated lenalidomide and dexamethasone without significant toxicity; three patients achieved complete response, and three had partial response. This study highlights RDD's diverse extra-nodal manifestations. Lenalidomide combined with dexamethasone is an effective and well-tolerated treatment option for select patients, especially those with refractory disease. Broad utilization of NGS and PET-CT can positively influence management decisions.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 11","pages":"4467 - 4476"},"PeriodicalIF":3.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report. 在慢性髓性白血病中发现涉及 9q34、22q11.2 和 5q22 的新型隐性变异染色体重排，导致 ins(9;22) 和 t(5;22)：一份病例报告。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-27 DOI: 10.1007/s00277-024-05966-8

Firoz Ahmad, Amisha Shah, Meenu Angi, Qurratulain Narmawala, Isha Gupta, Pooja Chaudhary, Ekta Jajodia, Toral Vaishnani, Naman Manguika, Moquitul Haque, Jigar Suthar, Lokesh Patel, Dhanlaxmi Shetty, Spandan Chaudhary, Neeraj Arora

{"title":"Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report.","authors":"Firoz Ahmad, Amisha Shah, Meenu Angi, Qurratulain Narmawala, Isha Gupta, Pooja Chaudhary, Ekta Jajodia, Toral Vaishnani, Naman Manguika, Moquitul Haque, Jigar Suthar, Lokesh Patel, Dhanlaxmi Shetty, Spandan Chaudhary, Neeraj Arora","doi":"10.1007/s00277-024-05966-8","DOIUrl":"https://doi.org/10.1007/s00277-024-05966-8","url":null,"abstract":"<p><p>Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic stem cells characterized by the aberrant production and uncontrolled proliferation of mature granulocytes with normal cell differentiation. The Philadelphia (Ph) chromosome resulting from reciprocal translocation between chromosomes 9 and 22 is the main genetic molecular hallmark of CML seen in more than 90% of the patients. However, about 5-10% of CML patients show a variant genetic rearrangement, involving one or more chromosomes in addition to 9 and 22. Herein, we describe the results of hematological, cytogenetic, fluorescence in situ hybridization (FISH), and high-end molecular analysis in a 77-year-old man diagnosed with CML. The combination of conventional cytogenetic analysis along with metaphase FISH and whole chromosomal paint revealed a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22, resulting in ins(9;22) and t(5;22). At the molecular level, using PCR, myeloid NGS panels, and whole transcriptome analyses, we showed that this complex rearrangement indeed resulted in the formation of the BCR::ABL1 e13a2 major fusion transcript. No additional somatic mutations or kinase domain mutations were identified, thereby suggesting that the current case is indeed genetically homogeneous. This study provided strong evidence to support the idea that insertion-derived BCR::ABL1 fusions often involve complex chromosomal abnormalities that are overlooked by conventional cytogenetics but can be identified by a combination of conventional, molecular cytogenetics, and high-end NGS studies.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms 作为 BCR-ABL 阴性骨髓增殖性肿瘤预后生物标志物的中性粒细胞与淋巴细胞比率和血小板与淋巴细胞比率

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-27 DOI: 10.1007/s00277-024-06023-0

Mirjana Cvetković, Isidora Arsenović, Mihailo Smiljanić, Marta Sobas, Andrija Bogdanović, Danijela Leković

{"title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms","authors":"Mirjana Cvetković, Isidora Arsenović, Mihailo Smiljanić, Marta Sobas, Andrija Bogdanović, Danijela Leković","doi":"10.1007/s00277-024-06023-0","DOIUrl":"10.1007/s00277-024-06023-0","url":null,"abstract":"<div><p>Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been associated with increased risk of thrombosis, cardiovascular mortality, but their role in myeloproliferative neoplasms (MPN) remains unclear. We analyzed NLR and PLR as prognostic markers for thrombosis and overall survival (OS) in the study that included 461 consecutive MPN patients who were diagnosed from 2018 to 2022 at University center. Twenty age-matched patients without hematological disorder were used as controls. NLR and PLR were significantly increased in whole MPN group compared to controls. NLR was highest in PV > PMF > ET (<i>p</i> < 0.001) while PLR was highest in ET > PMF > PV (<i>p</i> < 0.001). Thrombosis occurrence during follow-up correlated with NLR, NLR ≥ 4.5, presence of ≥ 2 CV factors and previous thrombosis. Arterial thrombosis was associated with previous thrombosis, NLR and NLR ≥ 4.5. Similarly in venous thrombosis previous thrombosis was risk factor, together with NLR, NLR ≥ 4.5, PLR, but also secondary malignancy and female gender. In multivariate Cox model, most important factors for thrombosis development during follow-up were previous thrombosis, NLR ≥ 4.5 and PLR ≥ 500; for arterial thrombosis, NLR ≥ 4.5 and previous thrombosis; for venous thrombosis PLR ≥ 500 and previous thrombosis. Patients with pre-PMF had significantly higher NLR than ET patients. In multivariate Cox regression model, most important factors associated with survival were NLR ≥ 4.5 and PLR ≥ 500. This study highlights strong prognostic correlation of NLR ≥ 4.5 and PLR ≥ 500 with development of thrombosis and OS in MPN. Besides previous thrombosis, most important factor associated with development of arterial thrombosis is NLR ≥ 4.5 and for venous PLR ≥ 500. Our results revealed that NLR ≥ 4.5 could be used as additional marker to distinguish ET from prePMF.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 11","pages":"4545 - 4556"},"PeriodicalIF":3.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia 与伊曲康唑联合治疗急性髓性白血病时，venetoclax 的谷浓度升高。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-27 DOI: 10.1007/s00277-024-05845-2

Masao Hagihara, Takeo Yasu, Yoshito Gando, Tomiyuki Sugi, Shiori Nakashima, Yui Imai, Hirofumi Nakano, Tomoyuki Uchida, Morihiro Inoue

{"title":"Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia","authors":"Masao Hagihara, Takeo Yasu, Yoshito Gando, Tomiyuki Sugi, Shiori Nakashima, Yui Imai, Hirofumi Nakano, Tomoyuki Uchida, Morihiro Inoue","doi":"10.1007/s00277-024-05845-2","DOIUrl":"10.1007/s00277-024-05845-2","url":null,"abstract":"<div><p>The administration of venetoclax (Ven) with azacitidine (Aza) was used as induction or salvage therapy for 34 patients with acute myeloid leukemia (AML) in our institute. An itraconazole oral solution (ITCZ-OS) was administered to 17 patients (50%) as antifungal prophylaxis. The trough concentration of Ven was significantly higher in patients treated with ITCZ than in those who were not (median values, 1.31 μg/mL vs. 0.64 μg/mL; <i>p</i> = 0.0072). Ven concentrations were > 3 μg/mL in some patients treated with ITCZ and the patient with the highest Ven concentration (5.58 μg/mL) expired after grade 4 neutropenia persisted for more than 50 days after the 1st cycle of Ven/Aza. It was also found that the group with concentrations equal to or above 1.29 μg/mL showed a significantly higher rate of achieving CR or CRi (<i>p</i> = 0.039). In conclusion, the measurement of Ven concentrations in AML cases is essential in daily clinical practice, particularly in those receiving antifungal prophylaxis.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 11","pages":"4497 - 4502"},"PeriodicalIF":3.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

15-year remission in refractory FLT3-mutated AML attained by sorafenib 索拉非尼治疗难治性FLT3突变急性髓细胞白血病15年取得缓解。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-25 DOI: 10.1007/s00277-024-06012-3

Christoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, Robert Zeiser, Justus Duyster, Jürgen Finke, Michael Lübbert

引用次数: 0

Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies. 接受利妥昔单抗治疗的非霍奇金淋巴瘤患者的间质性肺病表现出不同的特征。

IF 3 3区医学

Annals of Hematology Pub Date : 2024-09-25 DOI: 10.1007/s00277-024-06013-2

Wailong Zou, Jia Zhang, Yulin Li, Zhe Zhang, Rui Yang, Yaxin Yan, Weihua Zhu, Feng Ma, Piping Jiang, Yumin Wang, Xinjun Zhang, Jichao Chen

{"title":"Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies.","authors":"Wailong Zou, Jia Zhang, Yulin Li, Zhe Zhang, Rui Yang, Yaxin Yan, Weihua Zhu, Feng Ma, Piping Jiang, Yumin Wang, Xinjun Zhang, Jichao Chen","doi":"10.1007/s00277-024-06013-2","DOIUrl":"https://doi.org/10.1007/s00277-024-06013-2","url":null,"abstract":"<p><p>Although the incidence and outcomes of rituximab-induced interstitial lung disease (RILD) have been partially reported, there are no systematic studies on the characteristics and types of RILD. This study aimed to investigate the clinical characteristics, bronchoalveolar lavage (BAL) findings, and treatment course of RILD in patients with non-Hodgkin lymphoma. We retrospectively analyzed the data from 321 patients with non-Hodgkin lymphoma who developed RILD between 2020 and 2022. The extent, distribution, and radiologic patterns of interstitial lung disease were determined using high-resolution computed tomography of the chest. BAL was performed in 299 (93.1%) patients to determine cellular distribution patterns and identify pathogenic microorganisms using metagenomic next-generation sequencing. All patients received combination therapy, with cyclophosphamide, doxorubicin, vincristine, and prednisone being the most commonly administered regimens. The median time from treatment to RILD development was 1.7 months. In the 217 patients who underwent metagenomic next-generation sequencing, 179 pathogenic microorganisms were detected, including 77 (43.0%) bacteria, 45 (25.1%) viruses, 28 (15.6%) Pneumocystis jirovecii strains, 17 (9.5%) fungi, 6 (3.5%) Mycobacterium tuberculosis, and 6 (3.5%) atypical pathogens. All RILD diagnoses were based on multidisciplinary team discussions and compliance with international standards. In conclusion, RILD exhibits a range of radiological and BAL patterns, reflecting different interstitial lung disease types. The most common patterns of RILD are infectious lung disease, organizing pneumonia, and nonspecific interstitial pneumonia. These findings enhance the understanding of RILD in patients with non-Hodgkin lymphoma and serve as a reference for best management guidelines in these patients.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0